Millipore Sigma Vibrant Logo

204906 Complement C5b,6 Complex, Human

Complement C5b,6 Complex, Human, is a native complement complex where the nascent C5b fragment is combined with C6 to form a stable complex.

Complement C5b,6 Complex, Human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
View Products on Sigmaaldrich.com
204906
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
204906-50UGCN
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 50 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8, and C9 to form the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8, and C9.
      Catalogue Number204906
      Brand Family Calbiochem®
      References
      ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
      Product Information
      FormLiquid
      FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Specific Activity≥2000 C5b,6H50 units/mg
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      204906-50UGCN 04055977219883

      Documentation

      Complement C5b,6 Complex, Human SDS

      Title

      Safety Data Sheet (SDS) 

      Complement C5b,6 Complex, Human Certificates of Analysis

      TitleLot Number
      204906

      References

      Reference overview
      Podack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-May-2008 RFH
      DescriptionNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8 and C9 to from the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8 and C9.
      FormLiquid
      FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Purity≥95% by SDS-PAGE
      Specific activity≥2000 C5b,6H50 units/mg
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
      Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.